{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:48:21Z","timestamp":1790092101355,"version":"4.0.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40273-022-01161-7","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T01:02:36Z","timestamp":1656464556000},"page":"715-724","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China"],"prefix":"10.1007","volume":"40","author":[{"given":"Yichen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huangqianyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luwen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1290-3827","authenticated-orcid":false,"given":"Xiaodong","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"issue":"9","key":"1161_CR1","doi-asserted-by":"publisher","first-page":"e212026","DOI":"10.1001\/jamaoncol.2021.2026","volume":"7","author":"KN Vokinger","year":"2021","unstructured":"Vokinger KN, Hwang TJ, Daniore P, et al. Analysis of launch and postapproval cancer drug pricing, clinical benefit, and policy implications in the US and Europe. JAMA Oncol. 2021;7(9):e212026. https:\/\/doi.org\/10.1001\/jamaoncol.2021.2026.","journal-title":"JAMA Oncol"},{"issue":"6","key":"1161_CR2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrclinonc.2017.31","volume":"14","author":"V Prasad","year":"2017","unstructured":"Prasad V, De Jes\u00fas K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017;14(6):381\u201390. https:\/\/doi.org\/10.1038\/nrclinonc.2017.31.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1161_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/s1470-2045(15)00449-0","volume":"17","author":"S Vogler","year":"2016","unstructured":"Vogler S, Vitry A, Babar ZU. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Lancet Oncol. 2016;17(1):39\u201347. https:\/\/doi.org\/10.1016\/s1470-2045(15)00449-0.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1161_CR4","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1200\/jop.2016.014431","volume":"13","author":"P Savage","year":"2017","unstructured":"Savage P, Mahmoud S, Patel Y, Kantarjian H. Cancer drugs: an international comparison of postlicensing price inflation. J Oncol Pract. 2017;13(6):e538\u201342. https:\/\/doi.org\/10.1200\/jop.2016.014431.","journal-title":"J Oncol Pract"},{"key":"1161_CR5","unstructured":"Hofmarcher T, Br\u00e5dvik G, Svedman C, Lindgren P, J\u00f6nsson B, Wilking N. Comparator report on cancer in Europe 2019\u2014disease burden, costs and access to medicines. https:\/\/ihe.se\/en\/publicering\/comparator-report-on-cancer-in-europe-2019\/. Accessed 1 May 2022."},{"key":"1161_CR6","unstructured":"IQVIA. Global Oncology Trends 2021. 2021. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/global-oncology-trends-2021"},{"issue":"2","key":"1161_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3322\/caac.21597","volume":"70","author":"J Cortes","year":"2020","unstructured":"Cortes J, Perez-Garc\u00eda JM, Llombart-Cussac A, et al. Enhancing global access to cancer medicines. CA Cancer J Clin. 2020;70(2):105\u201324. https:\/\/doi.org\/10.3322\/caac.21597.","journal-title":"CA Cancer J Clin"},{"key":"1161_CR8","unstructured":"World Health O. Technical report: pricing of cancer medicines and its impacts: a comprehensive technical report for the World Health Assembly Resolution 70.12: operative paragraph 2.9 on pricing approaches and their impacts on availability and affordability of medicines for the prevention and treatment of cancer. World Health Organization; 2018."},{"issue":"4","key":"1161_CR9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/14737167.2021.1884546","volume":"21","author":"B Godman","year":"2021","unstructured":"Godman B, Hill A, Simoens S, et al. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):527\u201340. https:\/\/doi.org\/10.1080\/14737167.2021.1884546.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"16","key":"1161_CR10","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1001\/jama.2014.13235","volume":"312","author":"PB Bach","year":"2014","unstructured":"Bach PB. Indication-specific pricing for cancer drugs. JAMA. 2014;312(16):1629\u201330. https:\/\/doi.org\/10.1001\/jama.2014.13235.","journal-title":"JAMA"},{"issue":"21","key":"1161_CR11","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1001\/jama.2018.5367","volume":"319","author":"JC Robinson","year":"2018","unstructured":"Robinson JC, Howell S, Pearson SD. Value-based pricing and patient access for specialty drugs. JAMA. 2018;319(21):2169\u201370. https:\/\/doi.org\/10.1001\/jama.2018.5367.","journal-title":"JAMA"},{"issue":"16","key":"1161_CR12","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1001\/jama.2018.11808","volume":"320","author":"MS Broder","year":"2018","unstructured":"Broder MS, Ortendahl JD. Defining value-based pricing of drugs. JAMA. 2018;320(16):1710. https:\/\/doi.org\/10.1001\/jama.2018.11808.","journal-title":"JAMA"},{"issue":"6s","key":"1161_CR13","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jval.2019.04.1918","volume":"22","author":"F Augustovski","year":"2019","unstructured":"Augustovski F, McClellan MB. Current policy and practice for value-based pricing. Value Health. 2019;22(6s):S4-s6. https:\/\/doi.org\/10.1016\/j.jval.2019.04.1918.","journal-title":"Value Health."},{"issue":"1","key":"1161_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1257\/jep.29.1.139","volume":"29","author":"DH Howard","year":"2015","unstructured":"Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29(1):139\u201362. https:\/\/doi.org\/10.1257\/jep.29.1.139.","journal-title":"J Econ Perspect"},{"issue":"1","key":"1161_CR15","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1016\/s1470-2045(14)70375-4","volume":"16","author":"MK Wilson","year":"2015","unstructured":"Wilson MK, Karakasis K, Oza AM. Outcomes and endpoints in trials of cancer treatment: the past, present, and future. Lancet Oncol. 2015;16(1):e32-42. https:\/\/doi.org\/10.1016\/s1470-2045(14)70375-4.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1161_CR16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1001\/jamaoncol.2015.0373","volume":"1","author":"S Mailankody","year":"2015","unstructured":"Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol. 2015;1(4):539\u201340. https:\/\/doi.org\/10.1001\/jamaoncol.2015.0373.","journal-title":"JAMA Oncol"},{"issue":"12","key":"1161_CR17","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1111\/cas.13831","volume":"109","author":"E Satoh","year":"2018","unstructured":"Satoh E, Sasaki Y, Ohkuma R, et al. Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan. Cancer Sci. 2018;109(12):3896\u2013901. https:\/\/doi.org\/10.1111\/cas.13831.","journal-title":"Cancer Sci"},{"key":"1161_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2020.113042","volume":"258","author":"S Salas-Vega","year":"2020","unstructured":"Salas-Vega S, Shearer E, Mossialos E. Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US. Soc Sci Med. 2020;258: 113042. https:\/\/doi.org\/10.1016\/j.socscimed.2020.113042.","journal-title":"Soc Sci Med"},{"key":"1161_CR19","doi-asserted-by":"publisher","first-page":"j4543","DOI":"10.1136\/bmj.j4543","volume":"359","author":"D Cohen","year":"2017","unstructured":"Cohen D. Cancer drugs: high price, uncertain value. BMJ. 2017;359:j4543. https:\/\/doi.org\/10.1136\/bmj.j4543.","journal-title":"BMJ"},{"issue":"7","key":"1161_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40273-016-0413-0","volume":"34","author":"A Haycox","year":"2016","unstructured":"Haycox A. Why cancer? Pharmacoeconomics. 2016;34(7):625\u20137. https:\/\/doi.org\/10.1007\/s40273-016-0413-0.","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"1161_CR21","doi-asserted-by":"publisher","first-page":"e033728","DOI":"10.1136\/bmjopen-2019-033728","volume":"9","author":"F Trotta","year":"2019","unstructured":"Trotta F, Mayer F, Barone-Adesi F, et al. Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy. BMJ Open. 2019;9(12):e033728. https:\/\/doi.org\/10.1136\/bmjopen-2019-033728.","journal-title":"BMJ Open"},{"key":"1161_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2021-006196","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Wushouer H, Han S, et al. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China. BMJ Glob Health. 2021. https:\/\/doi.org\/10.1136\/bmjgh-2021-006196.","journal-title":"BMJ Glob Health"},{"issue":"6","key":"1161_CR23","doi-asserted-by":"publisher","first-page":"464","DOI":"10.5582\/bst.2019.01339","volume":"13","author":"M Tang","year":"2020","unstructured":"Tang M, Song P, He J. Progress on drug pricing negotiations in China. Biosci Trends. 2020;13(6):464\u20138. https:\/\/doi.org\/10.5582\/bst.2019.01339.","journal-title":"Biosci Trends"},{"issue":"1","key":"1161_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2019-002256","volume":"5","author":"L Si","year":"2020","unstructured":"Si L, Xu L, Chen M, Jan S. Using strategic price negotiations to contain costs and expand access to medicines in China. BMJ Glob Health. 2020;5(1): e002256. https:\/\/doi.org\/10.1136\/bmjgh-2019-002256.","journal-title":"BMJ Glob Health"},{"key":"1161_CR25","unstructured":"Ministry of Human Resources and Social Security. Notice of the ministry of human resources and social security on issuing the national drug catalog for basic medical insurance, work- related injury insurance, and maternity insurance. 2021. http:\/\/www.mohrss.gov.cn\/SYrlzyhshbzb\/shehuibaozhang\/zcwj\/yiliao\/201707\/t20170718_274153.html"},{"key":"1161_CR26","unstructured":"National Healthcare Security Administration. Notice on including 17 anticancer medicines in \"national basic medical insurance, work-related injury insurance and childbirth insurance medicine list (Category B)\". http:\/\/www.nhsa.gov.cn\/art\/2018\/10\/10\/art_37_1057.html"},{"key":"1161_CR27","unstructured":"National Healthcare Security Administration. Notice on Including Year 2019 Negotiated Medicines in \"National Basic Medical Insurance, Work-related Injury Insurance and Childbirth Insurance Medicine List (Category B)\". 2021. http:\/\/www.nhsa.gov.cn\/art\/2019\/11\/28\/art_38_2056.html"},{"key":"1161_CR28","unstructured":"National Healthcare Security Administration. Notice on issuing the national drug catalog for basic medical insurance, work-related injury insurance, and maternity insurance (2020 edition). 2021. http:\/\/www.nhsa.gov.cn\/art\/2020\/12\/28\/art_37_4220.html"},{"key":"1161_CR29","unstructured":"Beijing Medicine Sunshine Purchasing. https:\/\/yp.bjmbc.org.cn\/view\/index\/guide.html. Accessed 1 Apr 2021."},{"key":"1161_CR30","unstructured":"Beijing Medical Insurance Public Service. https:\/\/fw.ybj.beijing.gov.cn\/hallEnter\/#\/serviceGuidelines. Accessed 1 May 2022."},{"key":"1161_CR31","unstructured":"Beijing Cancer Hospital. 2021. https:\/\/www.bjcancer.org"},{"key":"1161_CR32","unstructured":"Peking University First Hospital. 2021. https:\/\/www.pkuph.cn\/sufferer_services.html"},{"key":"1161_CR33","unstructured":"Peking University Third Hospital. 2021. http:\/\/www.puh3.net.cn"},{"issue":"7","key":"1161_CR34","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1200\/jco.1998.16.7.2297","volume":"16","author":"MJ Ratain","year":"1998","unstructured":"Ratain MJ. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol. 1998;16(7):2297\u20138. https:\/\/doi.org\/10.1200\/jco.1998.16.7.2297.","journal-title":"J Clin Oncol"},{"key":"1161_CR35","unstructured":"World Health Organization Collaborating Centre for Drug Statistics Methodology. Definition and general considerations of the defined daily dose. 2021. https:\/\/www.whocc.no\/ddd\/definition_and_general_considera\/"},{"issue":"5","key":"1161_CR36","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/s1470-2045(20)30139-x","volume":"21","author":"KN Vokinger","year":"2020","unstructured":"Vokinger KN, Hwang TJ, Grischott T, et al. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. Lancet Oncol. 2020;21(5):664\u201370. https:\/\/doi.org\/10.1016\/s1470-2045(20)30139-x.","journal-title":"Lancet Oncol"},{"key":"1161_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01112-8","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Pharmacoeconomics. 2022. https:\/\/doi.org\/10.1007\/s40273-021-01112-8.","journal-title":"Pharmacoeconomics"},{"key":"1161_CR38","unstructured":"Centre for Drug Evaluation NMPA. Launched drug information. https:\/\/www.cde.org.cn\/main\/xxgk\/listpage\/b40868b5e21c038a6aa8b4319d21b07d. Accessed 1 May 2022."},{"key":"1161_CR39","unstructured":"Centre for Drug Evaluation NMPA. List of launched drugs in China. https:\/\/www.cde.org.cn\/hymlj\/index. Accessed 1 May 2022"},{"issue":"2","key":"1161_CR40","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115\u201332. https:\/\/doi.org\/10.3322\/caac.21338.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"1161_CR41","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1377\/hlthaff.2019.01122","volume":"39","author":"VD Lauenroth","year":"2020","unstructured":"Lauenroth VD, Kesselheim AS, Sarpatwari A, Stern AD. Lessons from the impact of price regulation on the pricing of anticancer drugs in Germany. Health Aff (Millwood). 2020;39(7):1185\u201393. https:\/\/doi.org\/10.1377\/hlthaff.2019.01122.","journal-title":"Health Aff (Millwood)."},{"issue":"21","key":"1161_CR42","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1001\/jama.2018.4871","volume":"319","author":"A Kaltenboeck","year":"2018","unstructured":"Kaltenboeck A, Bach PB. Value-based pricing for drugs: theme and variations. JAMA. 2018;319(21):2165\u20136. https:\/\/doi.org\/10.1001\/jama.2018.4871.","journal-title":"JAMA"},{"issue":"4","key":"1161_CR43","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/cam4.2058","volume":"8","author":"DM Jiang","year":"2019","unstructured":"Jiang DM, Chan KKW, Jang RW, et al. Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: clinical benefit and price considerations. Cancer Med. 2019;8(4):1584\u201393. https:\/\/doi.org\/10.1002\/cam4.2058.","journal-title":"Cancer Med"},{"issue":"7","key":"1161_CR44","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1002\/cncr.32639","volume":"126","author":"DA Ezeife","year":"2020","unstructured":"Ezeife DA, Dionne F, Fares AF, et al. Value assessment of oncology drugs using a weighted criterion-based approach. Cancer. 2020;126(7):1530\u201340. https:\/\/doi.org\/10.1002\/cncr.32639.","journal-title":"Cancer"},{"key":"1161_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2020.11.031","volume":"145","author":"MA Rodwin","year":"2021","unstructured":"Rodwin MA, Mancini J, Duran S, et al. The use of \u201cadded benefit\u201d to determine the price of new anti-cancer drugs in France, 2004\u20132017. Eur J Cancer. 2021;145:11\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2020.11.031.","journal-title":"Eur J Cancer"},{"issue":"5","key":"1161_CR46","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40273-014-0144-z","volume":"32","author":"M Drummond","year":"2014","unstructured":"Drummond M, de Pouvourville G, Jones E, Haig J, Saba G, Cawston H. A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France. Pharmacoeconomics. 2014;32(5):509\u201320. https:\/\/doi.org\/10.1007\/s40273-014-0144-z.","journal-title":"Pharmacoeconomics"},{"issue":"24","key":"1161_CR47","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1200\/jco.2016.71.6894","volume":"35","author":"S Cheng","year":"2017","unstructured":"Cheng S, McDonald EJ, Cheung MC, et al. Do the American Society of Clinical Oncology Value framework and the European society of medical oncology magnitude of clinical benefit scale measure the same construct of clinical benefit? J Clin Oncol. 2017;35(24):2764\u201371. https:\/\/doi.org\/10.1200\/jco.2016.71.6894.","journal-title":"J Clin Oncol"},{"issue":"6-a Suppl","key":"1161_CR48","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.18553\/jmcp.2017.23.6-a.s13","volume":"23","author":"B Shah-Manek","year":"2017","unstructured":"Shah-Manek B, Galanto JS, Nguyen H, Ignoffo R. Value frameworks for the patient-provider interaction: a comparison of the ASCO value framework versus NCCN evidence blocks in determining value in oncology. J Manag Care Spec Pharm. 2017;23(6-a Suppl):S13-s20. https:\/\/doi.org\/10.18553\/jmcp.2017.23.6-a.s13.","journal-title":"J Manag Care Spec Pharm"},{"issue":"8","key":"1161_CR49","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1001\/jamaoncol.2019.0818","volume":"5","author":"R Saluja","year":"2019","unstructured":"Saluja R, Everest L, Cheng S, Cheung M, Chan KKW. Assessment of whether the American Society of Clinical Oncology\u2019s value framework and the European Society for Medical Oncology\u2019s magnitude of clinical benefit scale measure absolute or relative clinical survival benefit: an analysis of randomized clinical trials. JAMA Oncol. 2019;5(8):1188\u201394. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0818.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1161_CR50","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5639\/gabij.2019.0802.007","volume":"8","author":"B Godman","year":"2019","unstructured":"Godman B, Hill A, Simoens S, et al. Pricing of oral generic cancer medicines in 25 European countries; fi ndings and implications. GaBI J. 2019;8(2):49\u201370. https:\/\/doi.org\/10.5639\/gabij.2019.0802.007.","journal-title":"GaBI J."},{"key":"1161_CR51","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.vhri.2018.08.007","volume":"18","author":"SS Hasan","year":"2019","unstructured":"Hasan SS, Kow CS, Dawoud D, Mohamed O, Baines D, Babar ZU. Pharmaceutical policy reforms to regulate drug prices in the Asia Pacific region: the case of Australia, China, India, Malaysia, New Zealand, and South Korea. Value Health Reg Issues. 2019;18:18\u201323. https:\/\/doi.org\/10.1016\/j.vhri.2018.08.007.","journal-title":"Value Health Reg Issues."},{"key":"1161_CR52","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.socscimed.2018.07.004","volume":"211","author":"E MacKillop","year":"2018","unstructured":"MacKillop E, Sheard S. Quantifying life: understanding the history of quality-adjusted life-years (QALYs). Soc Sci Med. 2018;211:359\u201366. https:\/\/doi.org\/10.1016\/j.socscimed.2018.07.004.","journal-title":"Soc Sci Med"},{"issue":"6","key":"1161_CR53","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1001\/jamaoncol.2019.6846","volume":"6","author":"N Franzen","year":"2020","unstructured":"Franzen N, Ret\u00e8l VP, Schats W, van Harten WH. Evidence underlying policy proposals for sustainable anticancer drug prices: a systematic review. JAMA Oncol. 2020;6(6):909\u201316. https:\/\/doi.org\/10.1001\/jamaoncol.2019.6846.","journal-title":"JAMA Oncol"},{"issue":"23","key":"1161_CR54","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1001\/jama.2015.16843","volume":"314","author":"PB Bach","year":"2015","unstructured":"Bach PB, Pearson SD. Payer and policy maker steps to support value-based pricing for drugs. JAMA. 2015;314(23):2503\u20134. https:\/\/doi.org\/10.1001\/jama.2015.16843.","journal-title":"JAMA"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01161-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-022-01161-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01161-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T02:13:58Z","timestamp":1657332838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-022-01161-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1161"],"URL":"https:\/\/doi.org\/10.1007\/s40273-022-01161-7","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"assertion":[{"value":"23 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Guan reported receiving grants from Research on Equitable Access and Rational Use of Medicines sponsored by Peking University Health Science Center during the study. The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that there are no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"Not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All datasets presented in this study are included in the article\/Supplementary Material.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}},{"value":"YZ and XG conceptualized and designed the study. YC and RY collected and rechecked the data. YW conducted the data analysis. YZ drafted the manuscript. XG and HL provided critical revision of the manuscript. LS supervised the study and provided administrative support.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contribution statement"}}]}}